PolyPid (PYPD) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
PolyPid Ltd. has received a notification from Nasdaq regarding non-compliance with the minimum stockholders’ equity requirement, as their equity fell below the necessary $2.5 million. The company has until January 9, 2025, to submit a compliance plan, and potential outcomes from their ongoing Phase 3 clinical trial could help meet the equity requirements if certain conditions are met. Despite the notification, PolyPid’s shares will continue trading on Nasdaq during the grace period.
For further insights into PYPD stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- ZMI, TBAL: 2 Canadian Balanced ETFs to Shield Your Returns
- Class Action Lawsuit Against Paragon 28, Inc. (NYSE:FNA)
- 3 Penny Stocks to Watch Now, 11/29/24
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
